ArticleThe Indian journal of medical research2015
Comparative proteomic analysis of sequential isolates of Mycobacterium tuberculosis from a patient with pulmonary tuberculosis turning from drug sensitive to multidrug resistant.
Article in The Indian journal of medical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Fitness costs of Mycobacterium tuberculosis resistant to rifampicin is compensated by rapid Th2 polarization mediated by early and high IL-4 production during mice infection.Scientific reports · 2025Article
- Editorial: Pathogenesis, diagnostics, treatments ofFrontiers in cellular and infection microbiology · 2024Article
- Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye.Trends in immunology · 2023Review
- Sequence and Structural Motifs Controlling the Broad Substrate Specificity of the Mycobacterial Hormone-Sensitive Lipase LipN.ACS omega · 2023Article
- Systems Biology: New Insight into Antibiotic Resistance.Microorganisms · 2022Review
- Alterations in molecular response of Mycobacterium tuberculosis against anti-tuberculosis drugs.Molecular biology reports · 2022Review
- Evolution of Drug-ResistantFrontiers in microbiology · 2021Review
- Immunometabolism during Mycobacterium tuberculosis Infection.Trends in microbiology · 2020Review
- Significance of the Differential Peptidome in Multidrug-Resistant Tuberculosis.BioMed research international · 2019Article
- Biochemical Characterization of Isoniazid-resistantMolecular & cellular proteomics : MCP · 2018Article
- Key Issues in the Management of Multi-Drug Resistant Tuberculosis: A Case Report.Open access Macedonian journal of medical sciences · 2018Article
- Potential Alternative Strategy against Drug Resistant Tuberculosis: A Proteomics Prospect.Proteomes · 2018Review
- Cure of tuberculosis using nanotechnology: An overview.Journal of microbiology (Seoul, Korea) · 2018Review
- Evaluation of 5 Novel protein biomarkers for the rapid diagnosis of pulmonary and extra-pulmonary tuberculosis: preliminary results.Scientific reports · 2017Article
- Article
- Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis.Frontiers in microbiology · 2017Article
- Recent development of mass spectrometry and proteomics applications in identification and typing of bacteria.Proteomics. Clinical applications · 2016Review
- Proteomics of multidrug resistant Mycobacterium tuberculosis clinical isolates: a peep show on mechanism of drug resistance & perhaps more.The Indian journal of medical research · 2015Article
- Performance of Xpert MTB/RIF on Ascitic Fluid Samples for Detection of Abdominal Tuberculosis.Journal of laboratory physiciansArticle
- Tuberculosis Diagnosis and Management: Recent Advances.Journal of global infectious diseasesReview
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
objectivesTuberculosis is a major health problem in India, and the emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) strains of Mycobacterium tuberculosis (Mtb) has further complicated the situation. Though several studies characterizing drug sensitive and drug resistant strains are available in literature, almost all studies are done on unrelated strains. Therefore, the objective of this study was to compare the proteomic data of four sequential isolates of Mtb from a single patient who developed MDR-TB during the course of anti-tuberculosis therapy (ATT).
methodsIn this study, using two-dimensional (2D) gel electrophoresis and MALDI-TOF mass spectrometry, we compared and analyzed the cell lysate proteins of Mtb sequential clinical isolates from a patient undergoing anti-TB treatment. The mRNA expression levels of selected identified proteins were determined by quantitative real-time polymerase chain reaction (qRT-PCR).
resultsThe genotypes of all four isolates remained homologous, indicating no re-infection. The initial isolate (before treatment) was sensitive to all first-line drugs, but the consecutive isolates were found to be resistant to isoniazid (INH) and rifampicin (RIF) and developed mutations in the katG, inhA and rpoB. the intensities of 27 protein spots were found to be consistently overexpressed in INH and RIF resistant isolates. The most prominent and overexpressed proteins found during the development of drug resistance were GarA (Rv1827), wag31 (Rv2145c), Rv1437 and Rv2970c. INTERPRETATION &
conclusionsThis preliminary proteomic study provides an insight about the proteins that are upregulated during drug resistance development. These upregulated proteins, identified here, could prove useful as immunodiagnostic and possibly drug resistant markers in future. However, more studies are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.